ClinicalTrials.gg
RecruitingNCT07433777REFIND-ITUpdated Feb 25, 2026

Reference Intervals With Indirect Methods in Italy

An observational study in Reference Intervals, sponsored by Centro di Riferimento Oncologico - Aviano. Recruiting at 24 sites in Italy. Open to participants aged 0 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Centro di Riferimento Oncologico - Aviano · Observational

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,000,000
Ages
0 Years to 100 Years
Sex
All
01

Study summary

Reference intervals are an essential tool for the clinical interpretation of laboratory test results. Traditionally, these interval are determined using samples from healthy individuals, a process that is resource-intensive, time-consuming, and require the active recruitment of healthy volunteers.

In recent years, due to the increasing availability of electronic health record (EHR) databases and the growing number of laboratory tests, it is possible to determine the reference intervals indirectly. This approach relies on the analysis of routine data acquired in clinical laboratories, eliminating the need for active recruiting healthy subjects and significantly reducing costs. Moreover, the method has the potential to eliminate the selection bias of an ultra-healthy population typical of the direct methods. The indirect methods for determining reference intervals have evolved from simple strategies of isolating the healthy population using sample metadata, to sophisticated statistical models that effectively distinguish normal from pathological distributions. One of the advanced techniques, RefineR, has reached an excellent combination of accuracy, robustness, and computational efficiency, outperforming previous methods. It has been implemented as an open-source R package, facilitating its application in real-world settings.

In recognition of these advantages, the IFCC (International Federation of Clinical Chemistry and Laboratory Medicine), through its Committee on Reference Intervals and Decision Limits (C-RIDL), has promoted the adoption of indirect methods for determining reference intervals, highlighting the advantages of this strategy, including greater speed, lower costs, and the absence of a need to recruit healthy donors.

Furthermore, a recent study has highlighted age-related physiological variations in hemoglobin levels in elderly population. This underscores the need for defining age-specific reference intervals which are currently absent from most laboratory reports, potentially impacting diagnostic accuracy.

02

Conditions studied

  • Reference Intervals
03

In context

Lead sponsor

Centro di Riferimento Oncologico - Aviano is the lead sponsor of 51 studies on the registry; 36 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population consists of all patients undergoing routine laboratory testing during the year 2024 at the participating centers.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • no one

Exclusion criteria

Exclusion Criteria:

  • no one
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,000,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Define indirect reference intervals for complete blood count (CBC) parameters by analyzing large-scale retrospective routine laboratory data.

    Time frame: up to 3 years

Secondary outcomes

  1. Assess regional differences by comparing results across 10 Italian regions.

    Statistical heterogeneity will be assessed using Cochran's Q test, and I squared index

    Time frame: up to 3 years

  2. Establish age- and sex-specific reference intervals

    Time frame: up to 3 years

  3. Evaluate inter-instrument variations by considering results obtained from different analytical platforms.

    Statistical heterogeneity will be assessed using Cochran's Q test, and I squared index

    Time frame: up to 3 years

07

Study locations

1 of 24 sites recruiting
  • ASL Bari, Ospedale della Murgia, Altamura
    Altamura, Altamura, Italy
    Not yet recruiting
    • Diana Fuzio · Contactdiana.fuzio@asl.bari.it
    • Paola Nardiello · Principal investigator
    • Diana Fuzio · Principal investigator
  • Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona
    Ancona, Ancona, Italy
    Not yet recruiting
  • Azienda USL Toscana Sud Est, Arezzo
    Arezzo, Arezzo, Italy
    Not yet recruiting
  • Azienda ULSS 1 Dolomiti
    Belluno, Belluno, Italy
    Not yet recruiting
  • Azienda Ospedaliero-Universitaria Careggi, Firenze
    Florence, Firenze, Italy
    Not yet recruiting
  • IRCCS Istituto Clinico Humanitas, Milano
    Milan, Milano, Italy
    Not yet recruiting
  • IRCCS Ospedale San Raffaele, Milano
    Milan, Milano, Italy
    Not yet recruiting
    • Anna Carobene · Contactcarobene.anna@hsr.it
    • Anna Carobene · Principal investigator
    • Massimo Locatelli · Principal investigator
  • Azienda Ospedaliero-Universitaria di Modena
    Modena, Modena, Italy
    Not yet recruiting
    • Tommaso Fasano · Contactt.fasano@ausl.mo.it
    • Tommaso Pirotti · Principal investigator
    • Tommaso Fasano · Principal investigator
  • Bianalisi Carate Brianza, Monza e Brianza
    Monza, Monza, Italy
    Not yet recruiting
    • Tommaso Trenti · Contacttommaso.trenti@gmail.com
    • Michela Cuccorese · Principal investigator
    • Tommaso Trenti · Principal investigator
  • Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara
    Novara, Novara, Italy
    Not yet recruiting
  • Azienda Ospedale Università Padova
    Padova, Padova, Italy
    Not yet recruiting
    • Paola Galozzi · Contactpaola.galozzi@unipd.it
    • Andrea Padoan · Principal investigator
    • Paola Galozzi · Principal investigator
  • Azienda Ospedaliera Universitaria Policlinico 'Paolo Giaccone' di Palermo
    Palermo, Palermo, Italy
    Not yet recruiting
    • Marcello Ciaccio · Contactmarcello.ciaccio@unipa.it
    • Luisa Agnello · Principal investigator
    • Marcello Ciaccio · Principal investigator
  • Centro di Riferimento Oncolgico -IRCCS
    Aviano, Pordenone 33081, Italy
    Recruiting
    • Fabio Del Ben · Contactfabio.delben@cro.it · 0434659101
    • Fabio Del Ben · Principal investigator
  • Azienda Sanitaria Friuli Occidentale, Ospedale di Pordenone
    Pordenone, Pordenone, Italy
    Not yet recruiting
  • Azienda Ospedaliera Universitaria Senese,
    Siena, Siena, Italy
    Not yet recruiting
    • Roberto Guerranti · Contactguerranti@unisi.it
    • Marcello Fiorini · Principal investigator
    • Roberto Guerranti · Principal investigator
  • Azienda Sanitaria Universitaria Giuliano Isontina
    Trieste, Trieste, Italy
    Not yet recruiting
  • Azienda Sanitaria Universitaria Friuli Centrale, Ospedale di Udine
    Udine, Udine, Italy
    Not yet recruiting
  • AULSS 3 Serenissima, Ospedale di Mestre
    Mestre, Venezia, Italy
    Not yet recruiting
  • Azienda Ospedaliera Universitaria Integrata di Verona
    Verona, Verona, Italy
    Not yet recruiting
  • AULSS 8 Berica, Ospedale S. Bortolo di Vicenza
    Vicenza, Vicenza, Italy
    Not yet recruiting
  • Ospedale di Desio, ASST Brianza
    Desio, Italy
    Not yet recruiting
  • ASL5 Spezzino, La Spezia
    La Spezia, Italy
    Not yet recruiting
  • ASST Grande Ospedale Metropolitano Niguarda, Milano
    Milan, Italy
    Not yet recruiting
  • Azienda ULSS 2 Marca Trevigiana
    Treviso, Italy
    Not yet recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Jun 2028, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2026
First posted
Feb 25, 2026
StartActual
Oct 8, 2025
Primary completionEst.
Jun 1, 2028
CompletionEst.
Jun 1, 2028
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07433777
Lead sponsor
Centro di Riferimento Oncologico - Aviano
Responsible party
Sponsor
First posted
Feb 25, 2026
Start date
Oct 8, 2025
Primary completion
Jun 1, 2028 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Feb 25, 2026

Study contacts

Fabio Del Ben
Contact
fabio.delben@cro.it
0434659101

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion